XZ 120
Alternative Names: XZ-120Latest Information Update: 26 Feb 2024
At a glance
- Originator Shandong New Time Pharmaceutical Co LTD
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 16 Jan 2024 Preclinical trials in Solid tumours in China (IV) before January 2024 (NCT06206915)
- 16 Jan 2024 Shandong New Time Pharmaceutical Co., LTD plans phase-I trial for Solid tumours (Monotherapy, Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in February 2024 (IV, Injection) (NCT06206915)